In this section, we discuss the predictions made by AWESOM for three examples of xenobiotics: (A) durlobactam, a β-lactamase inhibitor used to treat bacterial pneumonia; (B) 2,4,6-trichlorobiphenyl (PCB 30), a carcinogenic compound formerly used in industrial and consumer products; and (C) etrasimod, an S1P receptors modulator used to treat ulcerative colitis (Figure ).